@entity3069 complex immune reconstitution XXXX : long term outcomes.

@entity1 @entity32 @entity404 @entity645 @entity3069 @entity791
BACKGROUND: To describe long term outcomes of @entity3069 complex (MAC) immune reconstitution @entity32 (IRIS). METHODS: Cases of MAC IRIS were retrospectively identified at four @entity645 clinics (Michigan, Maryland, Rhode Island, and Indiana) from 1996-2004. @entity1 were included if they were initially diagnosed with @entity791 and found to have evidence of focal MAC infection documented by tissue culture or PCR after initiating HAART, and at least 6 months of follow up. RESULTS: Among the 20 @entity1 included, the mean age was 40 years, mean @entity404 cell count was 24/mm3 at pretreatment baseline and 100/mm3 at time of MAC IRIS diagnosis. Sites of disease included lymph nodes (15 @entity1 [8 peripheral, 8 abdominal and 1 peripheral and abdominal]), gastrointestinal tract (7) and liver (3). Sixteen @entity1 (80%) responded to treatment and were disease free after a mean of 17.4 months of therapy for MAC IRIS; IRIS therapy was withdrawn in 6 without relapse. Four @entity1 (non-responder group) had persistent or relapsing disease despite 27 months of ongoing MAC IRIS treatment. At the time of resolution or last follow-up, the mean @entity404 cell count and viral load was 143/mm3 and 7,000 c/mL for responders, and 65/mm3 and 17,000 c/mL for non-responders, respectively. Most @entity1 with peripheral adenopathy were responders (7/8; 88%); many with abdominal adenopathy (4/8; 50%) were nonresponders. CONCLUSION: The majority of @entity1 with MAC IRIS eventually responded to treatment. Our sample size was not adequate to perform statistical analysis, but there was a tendency towards adequate @entity404 response to HAART and peripheral rather than intraabdominal adenopathy among responders.
